TARGET SAFETY · DUE DILIGENCE · REGULATORY TOXICOLOGY
A curated knowledge base does the heavy lifting across modalities and stages of development. Our experts validate the evidence and translate it into actionable insight.
Your team gets an expert second opinion without spending hours on the research.
Target selection
Target safetyDue diligence
Evidence & risksAsset assessment
Mechanism & liabilitiesPreclinical safety
ToxicologyRegulatory
Submission-ready evidenceyears of expert curation
scored, referenced relationships
person-years of manual curation by toxicologists and biologists
global pharma companies work with us
What our clients say
Top pharmaceutical companies rely on our expertise to support target evaluation, due diligence and safety decision-making.
We’ve worked with several providers, but Metisox’s reports are easier to work with. The structure and references are better, and the findings are immediately actionable. We can take the report and get to work.
Head of Toxicology
Global pharmaceutical company
I keep thinking we have another few days before the report arrives, and then it’s already in my inbox. You work incredibly fast, which is great, except it means I have to start working sooner.
VP, Computational Sciences
Global pharmaceutical company
Our team was overloaded, so we needed to assess a large number of targets quickly. Metisox took part of the workload off our hands, assessing 48 targets in just one month. This freed our team to focus on other priorities and gave us the evidence we needed for an informed acquisition decision.
Toxicology Group Lead
Global pharmaceutical company
Whether you are evaluating a new asset, assessing a target, investigating a safety signal or preparing for a regulatory decision, we connect the evidence and turn it into a decision-ready report.
Target safety assessment for a single target, a target family, a bispecific or an acquired portfolio, with risks ranked in one heat map. Includes off-target and secondary pharmacology.
Carcinogenicity risk assessment under ICH S1B(R1) and developmental and reproductive toxicity assessment under ICH S5(R3), written by experts. Apply all six WoE factors or focus on the factors most relevant to your question.
Due Diligence
A first-pass safety assessment of an asset in about 48 hours, followed by a deeper assessment where the risks are. Applicable from early target programmes through marketed products.
New Indications & Biomarkers
Map a mechanism to additional diseases and identify biomarkers and patient-stratification opportunities from clinical and omics data, including post-launch evidence.
Mechanism & Omics Interpretation
Interpret omics data and unexpected study findings in the context of toxicological endpoints, and trace observations back to likely biological mechanisms.
Cosmetic & Chemical Safety
Mechanistic hypotheses for NGRA, read-across, hazard screening, extractables and leachables.
Ways to work with Metisox
Work directly with our experts on complex scientific questions. We combine proprietary data, technology and multidisciplinary expertise to deliver fast, in-depth assessments and decision-ready insights.
Connect your AI tools to our curated proprietary knowledge base and bring structured, traceable scientific evidence into your existing workflows.
What’s unique about our knowledge base?
A curated scientific knowledge graph connects targets, proteins, compounds, pathways, diseases and toxicology endpoints.
200+ person-years of manual curation by toxicologists, molecular biologists and bioinformaticians, focused on safety rather than general biology.
Every relationship is typed, scored for confidence and direction of effect, and linked to the underlying evidence.
If there is no direct evidence, we say so. When evidence is limited, we follow connected nodes to surface relevant mechanistic evidence without inventing the gaps.
Every finding is linked to its source and reviewed by our experts.
Our team brings decades of expertise across pharmaceutical drug discovery. This spans scientific disciplines including toxicology, pharmacology, molecular biology and bioinformatics, as well as specialised expertise in biomarkers and diagnostics and experience across therapeutic areas such as rare diseases and neuroscience.
Across modalities and stages of development
Across toxicology, medicine and life sciences
Our proprietary knowledge base accelerates the work. Our experts remain responsible for the conclusion.
Collaboration
Our proprietary technology and experts contribute to large-scale European research collaborations. The knowledge and innovation generated through these programmes enrich our proprietary knowledge graph and strengthen the scientific insights we deliver to our customers.
Advancing precision toxicology through biomarker discovery and new approaches to chemical safety assessment.
Investigating rare diseases and the molecular mechanisms underlying cilia-related disorders.
Webinars
We regularly share our expertise in open, free webinars for the pharmaceutical community. No client relationship required.
FAQ